Chimeric Therapeutics (ASX:CHM) has received AU$4 million in non-dilutionary funding to develop its CHM CDH17, a cell therapy targeting cancer, according to a Thursday filing with the Australian bourse.
The funds, provided by an undisclosed US-based philanthropic family office, are non-refundable, with no further obligations, and no equity or intellectual property has been transferred, the filing said.
Chimeric clarified that the identity of the philanthropic family office does not have any material impact on the company's securities, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.